Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

129.50GBp
26 Nov 2014
Price Change (% chg)

-4.50p (-3.36%)
Prev Close
134.00p
Open
132.25p
Day's High
134.00p
Day's Low
129.00p
Volume
506,332
Avg. Vol
674,906
52-wk High
171.50p
52-wk Low
103.00p

VEC.L

Chart for VEC.L

About

Vectura Group plc (Vectura) is a developer of therapies principally for the treatment of respiratory diseases. The Company is engaged in developing treatments for respiratory diseases. Vectura’s products target diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The Company’s pharmaceutical business... (more)

Overall

Beta: -0.12
Market Cap (Mil.): £539.30
Shares Outstanding (Mil.): 402.46
Dividend: --
Yield (%): --

Financials

  VEC.L Industry Sector
P/E (TTM): -- 38.09 39.03
EPS (TTM): -0.02 -- --
ROI: -3.35 17.96 17.31
ROE: -3.65 18.76 18.22
Search Stocks

BRIEF-Vectura gets marketing nod for Airflusal Forspiro in Ireland and Czech Republic

* Approval in Ireland and Czech Republic for innovative respiratory inhaler airflusal forspiro

19 Nov 2014

BRIEF-Vectura names Andrew Oakley as CFO

* Oakley will succeed Paul Oliver as CFO, executive director, and company secretary effective from 1 January 2015 Source text for Eikon: Further company coverage:

18 Nov 2014

BRIEF-Vectura H1 rev up 14 pct

* Nva237 is expected to be filed in us by novartis in q4 2014 Source text for Eikon: Further company coverage:

18 Nov 2014

BRIEF-Vectura says partner Novartis signs marketing deal with Pfizer UK

* Announcement of commercial arrangement with Pfizer UK to promote Ultibro Breezhaler and Seebri Breezhaler in United Kingdom Source text for Eikon: Further company coverage:

04 Sep 2014

BRIEF-Vectura performance from April to date in line with board's expectations

* Product pipeline is progressing in line with board's expectations

19 Aug 2014

BRIEF-Vectura says in US collaboration agreement for VR506 asthma therapy

* Announces a further US collaboration agreement with a leading international pharmaceutical company for VR506 asthma therapy

30 Jun 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Peel Hunt
$35.00
Provider: Sadif Analytics Prime
$10.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks